PMV Pharmaceuticals, Inc. (PMVP)

NASDAQ: PMVP · Real-Time Price · USD
1.260
-0.020 (-1.56%)
At close: May 22, 2026, 4:00 PM EDT
1.270
+0.010 (0.79%)
After-hours: May 22, 2026, 4:51 PM EDT
Market Cap67.20M +46.3%
Revenue (ttm)n/a
Net Income-78.34M
EPS-1.48
Shares Out 53.33M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume163,285
Open1.280
Previous Close1.280
Day's Range1.250 - 1.310
52-Week Range0.850 - 1.880
Beta1.41
AnalystsStrong Buy
Price Target4.33 (+243.65%)
Earnings DateMay 12, 2026

About PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 54
Stock Exchange NASDAQ
Ticker Symbol PMVP
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for PMVP stock is "Strong Buy." The 12-month stock price target is $4.33, which is an increase of 243.65% from the latest price.

Price Target
$4.33
(243.65% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer

Oppenheimer lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $5 from $6 and keeps an Outperform rating on the shares following quarterly results and business update. Rezatapopt continu...

11 days ago - TheFly

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

“The first quarter was one of continued execution as we advance the PYNNACLE study and remain on track to target an NDA submission for rezatapopt for platinum-resistant/refractory ovarian cancer in…

12 days ago - TheFly

PMV Pharmaceuticals Quarterly report: Q1 2026

PMV Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.

12 days ago - Filings

PMV Pharmaceuticals Earnings release: Q1 2026

PMV Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.

12 days ago - Filings

PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed

PMV Pharmaceuticals (PMVP) announced a transition on its board of directors. Laurie Stelzer, who has served as a member of the board since 2020, has been appointed chair of the…

Other symbols: KLRA
4 weeks ago - TheFly

PMV Pharmaceuticals Announces Board Chair Transition

Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director...

4 weeks ago - GlobeNewsWire

PMV Pharmaceuticals Proxy statement: Proxy filing

PMV Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.

4 weeks ago - Filings

PMV Pharmaceuticals Proxy statement: Proxy filing

PMV Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.

4 weeks ago - Filings

PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI

Evercore ISI lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $4 from $16 and keeps an Outperform rating on the shares. The firm updated models among its small-to-mid…

5 weeks ago - TheFly

PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)

“2025 was an important and productive year for PMV Pharma as we reported positive Phase 2 interim data from the registrational PYNNACLE clinical trial and made significant progress in enrolling…

2 months ago - TheFly

PMV Pharmaceuticals sees cash runway to end of 2Q27

As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, compared to $183.3 million at December 31, 2024. Net cash used in operations…

2 months ago - TheFly

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm...

2 months ago - GlobeNewsWire

PMV Pharmaceuticals Earnings release: Q4 2025

PMV Pharmaceuticals released its Q4 2025 earnings on March 6, 2026, summarizing the period's financial results.

2 months ago - Filings

PMV Pharmaceuticals Annual report: Q4 2025

PMV Pharmaceuticals has published its Q4 2025 annual report on March 6, 2026.

2 months ago - Filings

PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Rezatapopt demonstrates strong efficacy and safety in heavily pretreated ovarian cancer, with a 46% ORR and 8-month median DOR. NDA submission is planned for Q1 2027, with global expansion and combination studies underway. US market potential is estimated at $350–$420 million.

2 months ago - Transcripts

PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM

PMV Pharmaceuticals (PMVP) announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harborin...

3 months ago - TheFly

PMV Pharmaceuticals Slides: Corporate presentation

PMV Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on February 5, 2026.

3 months ago - Filings

PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)

“I am incredibly proud of our team and their commitment to rapidly and efficiently advancing the PYNNACLE study,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.

6 months ago - TheFly

PMV Pharmaceuticals Earnings release: Q3 2025

PMV Pharmaceuticals released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.

6 months ago - Filings

PMV Pharmaceuticals Quarterly report: Q3 2025

PMV Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 12, 2025.

6 months ago - Filings

PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data

PMV Pharmaceuticals (PMVP) announced updated data from the Phase 2 pivotal portion of the ongoing PYNNACLE clinical trial. Results were presented in an oral presentation by Alison M. Schram, M.D.,…

7 months ago - TheFly

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...

7 months ago - GlobeNewsWire

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...

7 months ago - GlobeNewsWire

PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE

PMV Pharmaceuticals (PMVP) announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients wi...

9 months ago - TheFly

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PRINCETON, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm...

9 months ago - GlobeNewsWire